Skip to main content

Dr. Alexander A. Boucher, MD

Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
14
In the NPI registry since
2012
Medicare patients seen, 2024
27

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2012Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pediatric Hematology & Oncology Physician primary
    MN license 57181

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pediatric Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
27
Services billed
81
Patients’ average age
45

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Oxycodone Hcl
Other prescribers in Minneapolis, MN
45

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $17,055 in research payments for these studies, mostly to the institutions running them.

  • A phase 3B, prospeca phase 3B, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (RADAMTS-13, also known as bax 930/SHP655) in the prophylactic and on…
    Takeda Pharmaceuticals U.S.A., Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pediatric Hematology & Oncology clinicians in Minneapolis

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 8, 2024), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1194083675. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.